

# International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 70 Proposed INN not later than 30 June 1994**.

## Proposed International Nonproprietary Names: List 70

*Lists of proposed (1-65) and recommended (1-31) international nonproprietary names can be found in Cumulative List No. 8, 1992.*

*Proposed International Nonproprietary Name (Latin, English)*


*Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\**

abciximabum  
abciximab

immunoglobulin G (human-mouse monoclonal c7E3 clone p7E3V<sub>H</sub>hC<sub>γ4</sub> Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V<sub>K</sub>hC<sub>K</sub> light chain  
143653-53-6 *antithrombotic*


acidum incadronicum  
incadronic acid

[(cycloheptylamino)methylene]diphosphonic acid  
C<sub>8</sub>H<sub>19</sub>NO<sub>6</sub>P<sub>2</sub> 124351-85-5 *calcium regulator*



adatanserinum  
adatanserin


*N*-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-1-adamantanecarboxamide  
C<sub>22</sub>H<sub>31</sub>N<sub>5</sub>O 127266-56-2 *serotonin receptor antagonist*



**\*Action and Use:** *The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will be neither revised nor included in the Cumulative Lists of INNs.*

adelmidrolum  
adelmidroi

*N,N'*-bis(2-hydroxyethyl)nonanediamide  
C<sub>13</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub> 1675-66-7 *antiacne agent*




afovirsenum  
afovirsen

2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioguanilyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioadenilyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thioguanilyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-thymidine  
C<sub>192</sub>H<sub>250</sub>N<sub>57</sub>O<sub>107</sub>P<sub>19</sub>S<sub>19</sub> *antiviral*


aglepristonum  
aglepristone

11β-[*p*-(dimethylamino)phenyl]-17β-hydroxy-17-[(*Z*)-propenyl]estra-4,9-dien-3-one  
C<sub>29</sub>H<sub>37</sub>NO<sub>2</sub> 124478-60-0 *abortive (vet.)*




alnespironum  
alnespirone

(+)-(*S*)-*N*-[4-[(5-methoxy-3-chromanyl)propylamino]butyl]-1,1-cyclopentanediacetimide  
C<sub>26</sub>H<sub>38</sub>N<sub>2</sub>O<sub>4</sub> 138298-79-0 *antidepressant*




arteflenum  
arteflene

(1*S*,4*R*,5*R*,8*S*)-4-[(*Z*)-2,4-bis(trifluoromethyl)styryl]-4,8-dimethyl-2,3-dioxabicyclo[3.3.1]nonan-7-one  
C<sub>19</sub>H<sub>18</sub>F<sub>6</sub>O<sub>3</sub> 123407-36-3 *antimalarial*




batimastatum  
batimastat

(2*S*,3*R*)-5-methyl-3-[[ $(\alpha S)$ - $\alpha$ -(methylcarbamoyl)phenethyl]carbamoyl]-2-  
[[2-thienylthio)methyl]hexanohydroxamic acid  
 $C_{23}H_{31}N_3O_4S_2$  130370-60-4 *antineoplastic*




besipirdinum  
besipirdine

1-(propyl-4-pyridylamino)indole  
 $C_{16}H_{17}N_3$  119257-34-0 *nootropic agent*




bicalutamidum  
bicalutamide

( $\pm$ )-4'-cyano- $\alpha$ , $\alpha$ , $\alpha$ -trifluoro-3-[(*p*-fluorophenyl)sulfonyl]-2-methyl-*m*-lactotoluidide  
 $C_{18}H_{14}F_4N_2O_4S$  90357-06-5 *antiandrogen*




bosentanum  
bosentan

*p*-*tert*-butyl-*N*-[6-(2-hydroxyethoxy)-5-(*o*-methoxyphenoxy)-2-(2-pyrimidinyl)-  
4-pyrimidinyl]benzenesulfonamide  
 $C_{27}H_{29}N_5O_6S$  147536-97-8 *endothelin receptor antagonist*



candocuronii iodidum  
candocuronium iodide

17 $\alpha$ ,17 $\alpha$ -dimethyl-3 $\beta$ -(1-methylpyrrolidinio)-17 $\alpha$ -azonia-*D*-homoandrost-5-ene  
diiodide  
 $C_{26}H_{46}I_2N_2$  54278-85-2 *neuromuscular receptor antagonist*



capromabum  
capromab

immunoglobulin G 1 (mouse monoclonal 7E11-C5.3 anti-human prostatic carcinoma  
cell), disulfide with mouse monoclonal 7E11-C5.3 light chain, dimer  
151763-64-3 *diagnostic agent*

Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


certoparinum natricum  
certoparin sodium

Sodium salt of depolymerized heparin obtained by isoamyl nitrite degradation of heparin from pork intestinal mucosa; the majority of the components have a 2-O-sulfo- $\alpha$ -L-idopyranosuronic acid structure at the non reducing end and a 6-O-sulfo-2,5-anhydro-D-mannose structure at the reducing end of their chain; the average relative molecular mass is 5000 to 7000; at least 70 per cent less than 10 000; the degree of sulfatation is 2 to 2,5 per disaccharidic unit.

*anticoagulant*


cinalukastum  
cinalukast

3'-[(E)-2-(4-cyclobutyl-2-thiazolyl)vinyl]-2,2-diethylsuccinanic acid  
C<sub>23</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>S 128312-51-6 *antiasthmatic*




dapabutanum  
dapabutan

( $\pm$ )-3-[[3-(dodecylamino)propyl]amino]butyric acid  
C<sub>19</sub>H<sub>40</sub>N<sub>2</sub>O<sub>2</sub> 6582-31-6 *antiseptic*




darifenacinum  
darifenacin

(S)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]- $\alpha,\alpha$ -diphenyl-3-pyrrolidineacetamide  
C<sub>28</sub>H<sub>30</sub>N<sub>2</sub>O<sub>2</sub> 133099-04-4 *muscarin receptor antagonist*



denotivirum  
denotivir

5-benzamido-4'-chloro-3-methyl-4-isothiazolecarboxanilide  
C<sub>18</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>2</sub>S 51287-57-1 *antiviral*




desirudinum  
desirudin

63-desulfohirudin (*Hirudo medicinalis* isoform HV2)  
C<sub>287</sub>H<sub>440</sub>N<sub>80</sub>O<sub>110</sub>S<sub>6</sub> 120993-53-5 *anticoagulant*

desmeninolum  
desmeninol

( $\pm$ )-2-hydroxy-4-(methylthio)butyric acid  
C<sub>6</sub>H<sub>10</sub>O<sub>3</sub>S 120-91-2 *amino acid analogue*



detumomabum  
detumomab

immunoglobulin (mouse monoclonal SPECIFID anti-human B lymphoma cell)  
disulfide with mouse monoclonal SPECIFID light chain, dimer  
145832-33-3 *immunomodulator*


Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

dexketoprofenum  
dexketoprofen

(+)-(S)-*m*-benzoylhydratropic acid  
C<sub>16</sub>H<sub>14</sub>O<sub>3</sub> 22161-81-5

*non-steroidal anti-inflammatory,  
analgesic*



dornasum alfa  
dornase alfa


deoxyribonuclease (human clone 18-1 protein moiety)  
C<sub>1321</sub>H<sub>1995</sub>N<sub>339</sub>O<sub>396</sub>S<sub>9</sub> 143831-71-4

*enzyme*

elopiprazolum  
elopiprazole

1-(7-benzofuranyl)-4-[[5-(*p*-fluorophenyl)pyrrol-2-yl]methyl]piperazine  
C<sub>23</sub>H<sub>22</sub>FN<sub>3</sub>O 115464-77-2

*antipsychotic*



emideltidum  
emideltide

L-tryptophyl-L-alanyl-glycyl-glycyl-L- $\alpha$ -aspartyl-L-alanyl-L-seryl-glycyl-L-glutamic acid  
C<sub>35</sub>H<sub>48</sub>N<sub>10</sub>O<sub>15</sub> 62568-57-4

*sedative*

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH

enlimomabum  
enlimomab


immunoglobulin G 2a (mouse monoclonal BI-RR-1 anti-human-antigen CD 54),  
disulfide with mouse monoclonal BI-RR-1 light chain, dimer  
142864-19-5

*immunomodulator*

geclosporinum  
geclosporin

cyclo[[[2*S*,3*R*,4*R*,6*E*]-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-norvalyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]  
C<sub>63</sub>H<sub>113</sub>N<sub>11</sub>O<sub>12</sub> 74436-00-3

*immunosuppressant*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


glenvastatinum  
glenvastatin

(4*R*,6*S*)-6-[(*E*)-2-[4-(*p*-fluorophenyl)-2-isopropyl-6-phenyl-3-pyridyl]vinyl]tetra-  
hydro-4-hydroxy-2*H*-pyran-2-one  
C<sub>27</sub>H<sub>26</sub>FNO<sub>3</sub> 122254-45-9 antihyperlipidaemic




icometasonii enbutas  
icometasone enbutate

9-chloro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-butyrate  
21-acetate  
C<sub>28</sub>H<sub>37</sub>ClO<sub>7</sub> 103466-73-5 corticosteroid




iganidipinum  
iganidipine

(±)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-  
(*m*-nitrophenyl)-3,5-pyridinedicarboxylate  
C<sub>28</sub>H<sub>38</sub>N<sub>4</sub>O<sub>6</sub> 119687-33-1 calcium channel blocker




ilepicimidum  
ilepicimide

1-[(*E*)-3,4-(methylenedioxy)cinnamoyl]piperidine  
C<sub>15</sub>H<sub>17</sub>NO<sub>3</sub> 82857-82-7 anticonvulsant



ilonidapum  
ilonidap

6-chloro-5-fluoro-3-[(*Z*)-α-hydroxy-2-thenylidene]-2-oxo-1-indolinecarboxamide  
C<sub>14</sub>H<sub>8</sub>ClFN<sub>2</sub>O<sub>3</sub>S 135202-79-8 non-steroidal anti-inflammatory




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


imitrodastum  
imitrodast

4,5-dihydro-2-(imidazol-1-ylmethyl)benzo[*b*]thiophene-6-carboxylic acid  
C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S 114686-12-3  
*antiasthmatic; thromboxane A<sub>2</sub>  
synthetase inhibitor*




iralukastum  
iralukast

7-[[[(1*S*,2*E*,4*Z*)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-[(*α**F*)-*α*-hydroxy-*m*-(trifluoromethyl)benzyl]-2,4-nonadieny]thio]-4-oxo-4*H*-1-benzopyran-2-carboxylic acid  
C<sub>38</sub>H<sub>37</sub>F<sub>3</sub>O<sub>8</sub>S 151581-24-7  
*antiasthmatic*




lafunimumum  
lafunimus

(*Z*)-*α*-cyano-*α*<sup>41</sup>,*α*<sup>41</sup>,*α*<sup>41</sup>-trifluoro-*β*-hydroxycyclopropaneacrylo-3',4'-xylylide  
C<sub>15</sub>H<sub>13</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub> 147076-36-6  
*immunodepressant*




lafutidinum  
lafutidine

(±)-2-(furfurylsulfinyl)-*N*-[(*Z*)-4-[[4-(piperidinomethyl)-2-pyridyl]oxy]-2-butenyl]=acetamide  
C<sub>22</sub>H<sub>29</sub>N<sub>3</sub>O<sub>4</sub>S 118288-08-7  
*histamine H<sub>2</sub>-receptor antagonist*




laurcetii bromidum  
laurcetium bromide

(carboxymethyl)dodecyldimethylammonium bromide, ethyl ester  
C<sub>18</sub>H<sub>38</sub>BrNO<sub>2</sub> 1794-75-8  
*antiseptic*



lecimibidum  
lecimibide

3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenylimidazol-2-yl)thio]pentyl]-1-heptylurea  
C<sub>34</sub>H<sub>40</sub>F<sub>2</sub>N<sub>2</sub>OS 130804-35-2  
*antihyperlipidaemic*



Proposed International  
Nonproprietary Name  
(Latin, English)


Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*

ledismasum  
ledismase

superoxide dismutase (human copper-zinc subunit), cyclic (57→146)-disulfide, dimer  
C<sub>679</sub>H<sub>1083</sub>N<sub>203</sub>O<sub>224</sub>S<sub>4</sub> 149394-67-2 enzyme


lemoxinolum  
lemoxinol

α-(4,6-dichloro-*m*-tolyl)oxy-ω-hydroxypoly(oxyethylene)  
Each *lemoxinol* name is followed by a number indicating the approximate number of oxyethylene groups present, e.g. *lemoxinol 5*, and the individual chemical names may contain a specific numerical syllable for the same purpose.  
C<sub>7</sub>H<sub>6</sub>OCl<sub>2</sub>(C<sub>2</sub>H<sub>4</sub>O)<sub>n</sub> antiseptic




letrozolum  
letrozole

4,4'-(1*H*-1,2,4-triazol-1-ylmethylene)dibenzonitrile  
C<sub>17</sub>H<sub>11</sub>N<sub>5</sub> 112809-51-5 antineoplastic




lexipafantum  
lexipafant

*N*-methyl-*N*-[[α-(2-methyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*p*-tolyl]sulfonyl]-*L*-leucine, ethyl ester  
C<sub>23</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub>S 139133-26-9 platelet activating factor antagonist




lopobutanum  
lopobutan

(±)-3-[[3-(dodecyloxy)propyl]amino]butyric acid  
C<sub>19</sub>H<sub>39</sub>NO<sub>3</sub> 6582-30-5 antiseptic



loviridum  
loviride

(±)-2-(6-acetyl-*m*-toluidino)-2-(2,6-dichlorophenyl)acetamide  
C<sub>17</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub> 147362-57-0 antiviral




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


lubeluzolum  
lubeluzole

(+)-(S)-4-(2-benzothiazolylmethylamino)- $\alpha$ -[(3,4-difluorophenoxy)methyl]-  
1-piperidineethanol  
 $C_{22}H_{25}F_2N_3O_2S$  144665-07-6 *neural protective agent*




mofarotenun  
mofarotene

4-[2-[*p*-(*E*)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]=  
phenoxy]ethyl]morpholine  
 $C_{29}H_{39}NO_2$  125533-88-2 *antineoplastic*




nupafantum  
nupafant

*N*-[(*S*)-1-(ethoxymethyl)-3-methylbutyl]-*N*-methyl- $\alpha$ -(2-methyl-1*H*-  
imidazo[4,5-*c*]pyridin-1-yl)-*p*-toluenesulfonamide  
 $C_{23}H_{32}N_4O_3S$  139133-27-0 *platelet activating factor antagonist*



olprinonum  
olprinone

1,2-dihydro-5-imidazo[1,2-*a*]pyridin-6-yl-6-methyl-2-oxonicotinonitrile  
 $C_{14}H_{10}N_4O$  106730-54-5 *cardiac stimulant, vasodilator*




Proposed International  
Nonproprietary Name  
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae  
Chemical Abstracts Service (CAS) registry number  
Action and Use\*


oxeclosporinum  
oxeclosporin

cyclo[[*(2S,3R,4R,6E)*-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-  
2-aminobutyryl-*N*-methylglycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl-L-alanyl-  
O-(2-hydroxyethyl)-D-seryl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl]  
C<sub>64</sub>H<sub>115</sub>N<sub>11</sub>O<sub>14</sub> 135548-15-1 immunosuppressant




pamicogrelum  
pamicogrel

ethyl 2-[4,5-bis(*p*-methoxyphenyl)-2-thiazolyl]pyrrole-1-acetate  
C<sub>25</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>S 101001-34-7 platelet aggregation inhibitor




pazinaclonum  
pazinaclone

(±)-8-[[2-(7-chloro-1,8-naphthyridin-2-yl)-3-oxo-1-isindolinyl]acetyl]-1,4-dioxo-  
8-azaspiro[4.5]decane  
C<sub>25</sub>H<sub>23</sub>ClN<sub>4</sub>O<sub>4</sub> 103255-66-9 anxiolytic




pobilukastum  
pobilukast

(*2S,3R*)-3-[(2-carboxyethyl)thio]-3-[*o*-(8-phenyloctyl)phenyl]lactic acid  
C<sub>26</sub>H<sub>34</sub>O<sub>5</sub>S 107023-41-6 antiasthmatic, leukotriene receptor antagonist




polixetonii chloridum  
polixetonium chloride

poly[oxyethylene(dimethyliminio)ethylene(dimethyliminio)ethylene dichloride]  
(C<sub>10</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>2</sub>O)<sub>n</sub> 31512-74-0 *disinfectant*




ramosetronum  
ramosetron

(-)-(R)-1-methylindol-3-yl 4,5,6,7-tetrahydro-5-benzimidazolyl ketone  
C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O 132036-88-5 *serotonin receptor antagonist*




rasagilinum  
rasagiline

(R)-N-2-propynyl-1-indanamine  
C<sub>12</sub>H<sub>13</sub>N 136236-51-6 *antiparkinsonian*




ricasetronum  
ricasetron

3,3-dimethyl-N-1αH,5αH-tropan-3α-yl-1-indolinecarboxamide  
C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O 117086-68-7 *serotonin receptor antagonist*




seratrodastum  
seratrodast

(±)-2,4,5-trimethyl-3,6-dioxo-ζ-phenyl-1,4-cyclohexadiene-1-heptanoic acid  
C<sub>22</sub>H<sub>26</sub>O<sub>4</sub> 112665-43-7 *antiasthmatic, thromboxane A<sub>2</sub> receptor antagonist*




spiroglumidum  
spiroglumide

(R)-γ-(3,5-dichlorobenzamido)-δ-oxo-8-azaspiro[4.5]decane-8-valeric acid  
C<sub>21</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub> 137795-35-8 *antiulcer*




sprodiamidum  
sprodiamide

aqua[N,N-bis[2-[(carboxymethyl)((methylcarbamoyl)methyl)amino]ethyl]-  
glycinato(3-)]dysprosium, hydrate  
C<sub>16</sub>H<sub>26</sub>DyN<sub>5</sub>O<sub>9</sub> · xH<sub>2</sub>O 138721-73-0 *diagnostic aid*




technetium (<sup>99m</sup>Tc) furifosminum  
technetium (<sup>99m</sup>Tc) furifosmin

(OC-6-13)-[[4,4'-[ethylenebis(nitrilomethylidene)]bis[dihydro-2,2,5,5-tetramethyl-  
3(2H)-furanonato]](2-)-N,N',O<sup>3</sup>,O<sup>3'</sup>]bis[tris(3-methoxypropyl)phosphine-P][<sup>99m</sup>Tc]=  
technetium(1+) chloride  
C<sub>44</sub>H<sub>84</sub>ClN<sub>2</sub>O<sub>10</sub>P<sub>2</sub><sup>99m</sup>Tc 142481-95-6 *radiocontrast medium*




telmisartanum  
telmisartan

4'-[[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-  
2-biphenylcarboxylic acid  
C<sub>33</sub>H<sub>30</sub>N<sub>4</sub>O<sub>2</sub> 144701-48-4 *angiotensin II receptor antagonist*




temoporfinum  
temoporfin

3,3',3'',3'''-(7,8-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol  
C<sub>44</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub> 122341-38-2 photosensitizer




tisartanum  
tisartan

1-[[N-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]valeramido]methyl]-1-cyclopentane-  
carboxylic acid  
C<sub>26</sub>H<sub>31</sub>N<sub>3</sub>O<sub>3</sub> 137882-98-5 angiotensin II receptor antagonist




tolafentrinum  
tolafentrine

(-)-4'-(-cis-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[c][1,6]=  
naphthyridin-6-yl)-p-toluenesulfonanilide  
C<sub>28</sub>H<sub>31</sub>N<sub>3</sub>O<sub>4</sub>S 139308-65-9 phosphodiesterase-inhibitor



tradecamidum  
tradecamide

13-hydroxy-N,N-dimethyltridecanamide  
C<sub>15</sub>H<sub>31</sub>NO<sub>2</sub> 132787-19-0 antiacne agent




votumumabum  
votumumab

immunoglobulin G3 (human monoclonal 88-BV59 heavy chain anti-human  
carcinoma-associated antigen), disulfide with human monoclonal 88-BV59  
κ-chain, dimer

148189-70-2 diagnostic agent


xanomelinum  
xanomeline

3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridine  
C<sub>14</sub>H<sub>23</sub>N<sub>3</sub>OS 131986-45-3 cholinergic




zankirenium  
zankiren

(S)-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-α-[(αS)-α-  
[[[4-methyl-1-piperazinyl]sulfonyl]methyl]hydrocinnamido]-4-thiazole=  
propionamide  
C<sub>35</sub>H<sub>55</sub>N<sub>5</sub>O<sub>6</sub>S<sub>2</sub> 138742-43-5 antihypertensive



zolasartanum  
zolasartan

1-[[[3-bromo-2-(o-1H-tetrazol-5-ylphenyl)-5-benzofuranyl]methyl]-2-butyl-4-  
chloroimidazole-5-carboxylic acid  
C<sub>24</sub>H<sub>20</sub>BrClN<sub>6</sub>O<sub>3</sub> 145781-32-4 angiotensin II receptor antagonist




### Names for Radicals and Groups

Some substances for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed international nonproprietary names.


dapropas  
dapropate

*N,N*-dimethyl-β-alanine  
C<sub>5</sub>H<sub>10</sub>NO<sub>2</sub>




edaminum  
edamine

ethylene diamine  
C<sub>2</sub>H<sub>6</sub>N<sub>2</sub>



fostedatum  
fostedate

tetradecyl hydrogen phosphate  
C<sub>14</sub>H<sub>30</sub>O<sub>4</sub>P



## AMENDMENTS TO PREVIOUS LISTS


Supplement to WHO Chronicle Vol. 36, No. 5, 1982

### Proposed International Nonproprietary Names (Prop. INN): List 48

p. 14 mitindomidum  
mitindomide

replace the chemical name, and the graphic formula by the following:

(1*R*\*,2*S*\*,3*R*\*,4*S*\*,5*R*\*,6*S*\*,7*S*\*,8*R*\*)-tricyclo[4.2.2.0<sup>2,5</sup>]dec-9-ene-3,4,7,8-tetracarboxylic 3,4:7,8-diimide



WHO Drug Information, Vol. 4, No. 2, 1990


### Proposed International Nonproprietary Names (Prop. INN): List 63

p. 6 gadodiamidum  
gadodiamide

replace the chemical name, CAS registry number, the molecular formula and the graphic formula by the following:

[*N,N*-bis[2-[(carboxymethyl)[methylcarbamoyl]methyl]amino]ethyl]glycinato=(3-)]gadolinium

$C_{16}H_{25}GdN_5O_8$  131410-48-5



WHO Drug Information, Vol. 4, No. 4, 1990

### Proposed International Nonproprietary Names (Prop. INN): List 64

p. 12 gadoteridolum  
gadoteridol

replace the chemical name by the following:

(±)-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato= [(3-)]gadolinium


WHO Drug Information, Vol. 6, No. 2, 1992

### Proposed International Nonproprietary Names (Prop. INN): List 67

p. 12 pendetidum  
pendetide

add the following CAS registry number:

148805-91-8

**Proposed International Nonproprietary Names (Prop. INN): List 68**p. 7 igmesinum  
igmesine*replace the action and use statement by the following:* $\sigma$  ligandp. 15 docetaxelum  
docetaxel*replace the chemical name, CAS registry number and the graphic formula by the following:**(2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5 $\beta$ -20-epoxy-1,2 $\alpha$ ,4,7 $\beta$ ,10 $\beta$ ,13 $\alpha$ -hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate*  
148408-66-6**Procedure and Guiding Principles**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only.